|Bid||17.96 x 800|
|Ask||17.90 x 1400|
|Day's Range||16.50 - 18.26|
|52 Week Range||4.47 - 19.67|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 04, 2020 - Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.00|
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.51% and 63.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported financial results for the second quarter ended June 30, 2020, and provided an update on clinical development programs.
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.